SOPH SEC Filings: 8-K, 10-Q, S-3 & 424B – SOPHiA GENETICS

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 3, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 4, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 5, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 7, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 15, 2022

News

TYPE

HEADLINE

FILED AT

6-K

SOPHiA GENETICS Reports Q3 2026 Financial Results

Nov 3, 2026

6-K

SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements for the Period Ended June 30, 2026

Aug 4, 2026

6-K

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

Jun 22, 2026

6-K

Amended Articles of Association for SOPHiA GENETICS SA

Jun 22, 2026

6-K

SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Sign MOU to Form Precision Medicine Joint Venture

Jun 4, 2026

6-K

SOPHiA GENETICS SA Publishes 2025 ESG Impact Summary

May 19, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jun 17, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: TD Cowen

Jun 16, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 75,000

Mar 6, 2026

424B5

August 2025 ATM

Aug 15, 2025

424B3

Aug 15, 2025

424B5

ATM | Offering amount: $50,000,000

Aug 8, 2023

Registrations

TYPE

HEADLINE

FILED AT

F-3

SHARE RESALE REGISTRATION

Mar 3, 2026

F-3

SHARE RESALE REGISTRATION EFFECTIVE, DATED 2025-08-15

Aug 5, 2025

F-3

August 2025 SHELF EFFECTIVE, DATED 2025-08-15

Aug 5, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 11, 2025

F-3/A

SHELF EFFECTIVE

Jul 22, 2024

F-3/A

SHARE RESALE REGISTRATION | Shares amount: 200,000 | Warrants amount: 200,000 | Warrants exercise price: $5.00 EFFECTIVE

Jul 1, 2024

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

NEWCARDOZA GEORGE (Reporting)

Nov 9, 2026

NEWMuken Ross (Reporting)

Nov 9, 2026

Menu Philippe (Reporting)

Oct 14, 2026

Xu Zhenyu (Reporting)

Oct 14, 2026

Camblong Jurgi (Reporting)

Oct 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 9, 2026

CORRESP

Form CORRESP - Correspondence

Mar 4, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 4, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 18, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 18, 2025

CORRESP

Form CORRESP - Correspondence

Aug 13, 2025

SOPHiA GENETICS S.A. SOPH · SEC Filings